October 31st, 2026October Social Media Mythbusters: 3 Viral Beauty Claims, DebunkedFrom “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.Read more
October 31st, 2026The Scariest Skin Care Trends Haunting Patients This HalloweenDermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.Read more
October 30th, 2026FDA Approves Tildrakizumab for Active Psoriatic ArthritisThe approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.Read more
October 30th, 2026The Aesthetic Edge: October 2026Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.Read more
October 30th, 2026FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.Read more
October 29th, 2026Elevate-Derm Summer Clinical PearlsElevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.Read more
October 28th, 2026How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment LandscapeAtopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.Read more
October 27th, 2026FDA Revises TB Evaluation Guidance for SKYRIZIUpdated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.Read more